𝔖 Bobbio Scriptorium
✦   LIBER   ✦

High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma

✍ Scribed by Raymond E. Lenhard Jr; Martin M. Oken; Janet M. Barnes; Richard L. Humphrey; John H. Glick; Murray N. Silverstein

Publisher
John Wiley and Sons
Year
1984
Tongue
English
Weight
420 KB
Volume
53
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The addition of interferon or high dose
The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma : Phase III Eastern Cooperative Oncology Group clinical trial EST 9486
✍ Martin M. Oken; Traci Leong; Raymond E. Lenhard Jr.; Philip R. Greipp; Neil E. K πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 133 KB πŸ‘ 2 views

## BACKGROUND. Interferon (IFN) has demonstrated activity in the treatment of patients with multiple myeloma. A previous Eastern Cooperative Oncology Group (ECOG) study suggested that the rates of complete response (CR) and survival were increased with a regimen that alternated IFN with chemothera

A Phase I dose escalation trial of conti
A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma
✍ Todd M. Zimmerman; David L. Grinblatt; Rebecca Malloy; Stephanie F. Williams πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 73 KB πŸ‘ 2 views

## BACKGROUND. Paclitaxel, an effective chemotherapeutic agent in the management of breast carcinoma, may have activity in women whose disease has recurred after high dose chemotherapy. With this is mind the authors explored the addition of a 120-hour continuous infusion of paclitaxel to a previou

High dose chlorambucil versus Binet's mo
High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia : Results of an international multicenter randomized trial
✍ Branimir Jaksic; Maura Brugiatelli; Ivo Krc; Hajna Losonczi; Jerzy Holowiecki; A πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 115 KB πŸ‘ 1 views

vanced and/or progressive disease was defined by high Total Tumor Mass (TTM) score (ΓΊ9), and/or short doubling time (DT) (Γ΅12 months), and/or bone marrow for the International Society for Chemo-Immunotherapy, Vienna failure. The response to therapy was defined by reduction of the initial TTM score.